Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Defect Action Levels To Follow GMP Reg - FDAer

This article was originally published in The Tan Sheet

Executive Summary

The establishment of defect action levels (DALs) for dietary supplement ingredients likely will be handled separately from FDA's pending proposed rule on Good Manufacturing Practice standards for supplements, FDA Consumer Safety Officer Karen Strauss told small business reps at a GMPs meeting in Salt Lake City, Utah Sept. 28.

You may also be interested in...



Single Identity Test For Botanicals "Makes Sense" - Israelsen

The use of multiple tests to confirm the identity of botanical ingredients is inappropriate, especially for small manufacturers of dietary supplements, Utah Natural Products Alliance Executive Director Loren Israelsen told FDAers at a public meeting on supplement GMPs in Salt Lake City, Utah Sept. 28.

Single Identity Test For Botanicals "Makes Sense" - Israelsen

The use of multiple tests to confirm the identity of botanical ingredients is inappropriate, especially for small manufacturers of dietary supplements, Utah Natural Products Alliance Executive Director Loren Israelsen told FDAers at a public meeting on supplement GMPs in Salt Lake City, Utah Sept. 28.

Single Identity Test For Botanicals "Makes Sense" - Israelsen

The use of multiple tests to confirm the identity of botanical ingredients is inappropriate, especially for small manufacturers of dietary supplements, Utah Natural Products Alliance Executive Director Loren Israelsen told FDAers at a public meeting on supplement GMPs in Salt Lake City, Utah Sept. 28.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel